Literature DB >> 17531835

The destructive alliance: interactions of leukocytes, cerebral endothelial cells, and the immune cascade in pathogenesis of multiple sclerosis.

Alireza Minagar1, April Carpenter, J Steven Alexander.   

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the human central nervous system (CNS) which develops predominantly in young adults with certain predisposing genetic characteristics, often following exposure to initiating environmental insult(s) including viral infections. The causes of MS remain elusive and no entire cure is in sight. However, it is well known that interactions between the immune system and the CNS play a central role in MS pathogenesis. Patients with MS generate CD4+ autoreactive T cells that at some point differentiate to Th1 phenotype cells, which are the major players in maintaining a continuous destructive immune response against brain and spinal cord antigens. Other significant participants in MS pathogenesis involved in the destruction of the target tissue are cerebral endothelial cells, CD8+ T cells, B cells, complement, autoantibodies, cytokines, and chemokines. The presence and interactions of all these participants further complicate the pathogenesis of MS, and make finding a cure for MS challenging. This chapter looks at the roles of these factors in the development of MS.

Entities:  

Mesh:

Year:  2007        PMID: 17531835     DOI: 10.1016/S0074-7742(07)79001-3

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  8 in total

1.  Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Authors:  Kelly Fellows; Tomas Uher; Richard W Browne; Bianca Weinstock-Guttman; Dana Horakova; Helena Posova; Manuela Vaneckova; Zdenek Seidl; Jan Krasensky; Michaela Tyblova; Eva Havrdova; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2015-08-04       Impact factor: 5.922

Review 2.  Losing your nerves? Maybe it's the antibodies.

Authors:  Betty Diamond; Patricio T Huerta; Paola Mina-Osorio; Czeslawa Kowal; Bruce T Volpe
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

3.  CCL3 production by microglial cells modulates disease severity in murine models of retinal degeneration.

Authors:  Hideo Kohno; Tadao Maeda; Lindsay Perusek; Eric Pearlman; Akiko Maeda
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

4.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

5.  Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions.

Authors:  Timothy J Seabrook; Amanda Littlewood-Evans; Volker Brinkmann; Bernadette Pöllinger; Christian Schnell; Peter C Hiestand
Journal:  J Neuroinflammation       Date:  2010-12-22       Impact factor: 8.322

6.  Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.

Authors:  Bianca Weinstock-Guttman; Murali Ramanathan; Karen Marr; David Hojnacki; Ralph H B Benedict; Charity Morgan; Eluen Ann Yeh; Ellen Carl; Cheryl Kennedy; Justine Reuther; Christina Brooks; Kristin Hunt; Makki Elfadil; Michelle Andrews; Robert Zivadinov
Journal:  BMC Neurol       Date:  2012-05-15       Impact factor: 2.474

7.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

Review 8.  The epidemiologic evidence linking autoimmune diseases and psychosis.

Authors:  Michael E Benros; William W Eaton; Preben B Mortensen
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.